Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
Status:
Terminated
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This prospective, multicenter, multinational, phase IV, interventional single-armed
(management) trial will focus on the safety, efficacy and cost-effectiveness of a new oral
anticoagulant in the treatment of patients with acute intermediate-risk PE based on validated
imaging (echocardiographic or CT angiographic) and laboratory biomarker (circulating levels
of cardiac troponins and natriuretic peptides) parameters and their combinations.